Cowen analyst Charles Rhyee said he views recent concerns over moderating brand inflation and their potential impact on drug distributors as "somewhat overblown," considering that he sees the issue as a 1%-2% headwind to adjusted EPS for the group. Additionally, Rhyee expects brand inflation to revert to normal levels once the current political rhetoric dies down. The analyst trimmed his price target on AmerisourceBergen (ABC) to $88 from $90, on Cardinal Health (CAH) to $86 from $89 and on McKesson (MCK) to $188 from $200 and keeps a Market Perform rating on all three stocks.